Top Markets
Coin of the day
Bellicum Pharmaceuticals, Inc. Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc.

BLCM
Rang in Aktien #38884
Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage... Bellicum Pharmaceuticals, Inc. (BLCM) operates as a clinical-stage biopharmaceutical firm dedicated to pioneering and advancing innovative cellular immunotherapies. Its primary objective is to combat blood cancers and solid tumors across domestic and global markets. Among its pipeline of experimental therapies are two key GoCAR-T candidates currently undergoing Phase 1/2 clinical evaluations. BPX-601, an autologous therapy, targets solid tumors that exhibit the prostate stem cell antigen. Additionally, BPX-603, a dual-switch GoCAR-T treatment, is being investigated for solid tumors characterized by the human epidermal growth factor receptor 2 (HER2) antigens. The company also features Rivo-cel, an allogeneic T cell therapy designed to improve patient prognoses in cases of leukemias, lymphomas, and various inherited blood disorders. Bellicum maintains strategic partnerships and licensing arrangements with several entities, including Adaptimmune Therapeutics plc, Agensys, Inc., BioVec Pharma, Inc., ARIAD Pharmaceuticals, Inc., and Baylor College of Medicine. Established in 2004, the company's corporate headquarters are located in Houston, Texas.
Aktienkurs
$0.07475
Zuletzt synchronisiert: 2024-03-04
Marktkapitalisierung
$755.60K
Veränderung (1 Tag)
-6.68%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Bellicum Pharmaceuticals, Inc. (BLCM)

Kategorie

Kursverlauf für Bellicum Pharmaceuticals, Inc. (BLCM)
Höchster Schlusskurs: $0.08 am 2024-03-01

Niedrigster Schlusskurs: $214.46 am 2014-12-01
Kursverlauf der Aktie von Bellicum Pharmaceuticals, Inc. von 2014 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2024 -58.98%
2023 -77.47%
2022 -48.69%
2021 -48.79%
2020 -67.81%
2019 -72.37%
2018 -59.58%
2017 -43.00%
2016 -22.19%
2015 -6.78%
2014 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$505.39 29.49%
US
$840.46 28.82%
NL
$730.39 6.94%
CH
$1.07K -6.40%
KR
$252.41 11.51%
BE